I’m writing this a few days after the end of ASH 2025, the annual meeting of the American Society of Hematology. As I mentioned…
Myeloma
VV169, an experimental cellular therapy being developed by Vyriad to treat myeloma, is expected to enter clinical testing in 2026, the…
This morning, while I was making myself a cup of coffee, I saw my reflection in the curved, stainless steel surface of the kettle as…
Johnson & Johnson (J&J) is asking the U.S. Food and Drug Administration (FDA) to approve a combination of two medications, Tecvayli (teclistamab) and…
A caregiver’s energy is a rare currency. When we spend it, we’re not doing so in single, large transactions. Instead, we’re making thousands of tiny…
Most people with hard-to-treat myeloma were still alive and free from disease progression two years after treatment with anito-cel (anitocabtagene autoleucel), an experimental cell…
As I write this, yesterday was Tuesday. Perhaps it was a great day for someone who got a promotion or received a gift. But for…
Most myeloma patients who started treatment at the Berenson Cancer Center — a clinic in California that specializes in myeloma care — lived…
Ever since my mum was diagnosed with myeloma, I’ve had to rewrite my vocabulary. My days are no longer filled with deadlines and projects,…
Thermo Fisher Scientific has received U.S. Food and Drug Administration (FDA) clearance for its EXENT System, an automated test that helps doctors diagnose multiple…
Recent Posts
- Early ovarian cancer trial seeking participants to test higher therapy dose
- As a caregiver, I’ve learned to read my mum’s daily forecast
- Short radiation course may ease painful myeloma bone lesions
- Nearly 70% of those given approved myeloma therapy alive 5 years later
- Latest AACR progress report on myeloma is a superpower of good news